Supernus Pharmaceuticals | SUPN - Betriebsaufwand

Aktienkurs
49.76
Täglich Wechseln
-0.63 -1.25%
Monatlich
-0.60%
Jährlich
54.44%
Q2 Prognose
48.70




Betriebsaufwand Veränderung Datum
Abbott USD 9.31B 104M 2026-03
ANI Pharmaceuticals USD 217.93M 287.88M 2025-12
Aurora Cannabis CAD 129.98M 16.05M 2025-12
Bristol-Myers Squibb USD 8.3B 10.25B 2025-12
Canopy Growth CAD 87.2M 6.22M 2025-12
Cara Therapeutics USD 5.94M 983K 2025-09
Corcept Therapeutics USD 197.64M 219K 2025-12
Eisai JPY 199.9B 16.22B 2025-12
Eli Lilly USD 10.31B 1.09B 2025-12
Novo Nordisk DKK 46.76B 3.99B 2025-12
Pacira USD 193.68M 27.32M 2025-12
Perrigo USD 1.03B 75.3M 2025-12
Pfizer USD 12.91B 79.89B 2025-12
Supernus Pharmaceuticals USD 197.75M 54.54M 2025-12
United Therapeutics USD 804.8M 5.79B 2025-12
Xeris Pharmaceuticals USD 69.03M 1.38M 2025-12